Last reviewed · How we verify
NCT06931444: BCES
The Beijing Childhood Eye Study
trial in Myopia in 3,760 participants. Enrolling by invitation.
1 August 2025
Quick facts
| Lead sponsor | Beijing Tongren Hospital |
|---|---|
| Status | ENROLLING BY INVITATION |
| Study type | OBSERVATIONAL |
| Enrollment | 3,760 |
| Start date | 1 January 2020 |
| Primary completion | 1 August 2025 |
| Estimated completion | 1 September 2025 |
| Sites | 1 location across China |
Conditions studied
- Myopia — all drugs for Myopia →
Sponsor
Beijing Tongren Hospital
Who can join
Adults 6 to 12, any sex, with Myopia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Axial myopia has emerged as the leading cause of irreversible vision loss in East Asia, driven by its progression to sight-threatening complications including myopic macular degeneration, retinal detachment, open-angle glaucoma, and other complications. In the current study, we aim to observe the natural course of the development , progression, and its associated factors in children
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06931444
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Myopia
Currently open trials in the same condition.
- NCT07284966 — Comfort and Vision With TOTAL30 Multifocal Lenses · recruiting
- NCT07078799 — Wavefront-guided LASIK Surgery Compared to Ray Tracing-Guided LASIK Surgery · NA · recruiting
- NCT07585877 — Effect of Branched-Chain Amino Acid Supplementation on Myopia Progression · NA · active not recruiting
- NCT07354945 — An Evaluation of Myopia Control Lenses on Wearing Experience in Myopic Children · NA · recruiting
- NCT07229365 — Children's Viewing Behavior · NA · recruiting
Other Beijing Tongren Hospital trials
Trials by the same sponsor.
- NCT07499791 — Absorbable Drug-Eluting Lacrimal Sac Stent for Recurrent Chronic Dacryocystitis · Phase 2 · not yet recruiting
- NCT07524959 — Antagonism of Neostigmine in Continuous Infusion of Mivacurium · NA · not yet recruiting
- NCT07525466 — Combination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatm · Phase 1, PHASE2 · recruiting
- NCT07472764 — Auricular Acupressure for Reducing Postoperative Emergence Agitation in Preschool Children · NA · not yet recruiting
- NCT07523737 — Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Dif · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06931444 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Beijing Tongren Hospital
- Last refreshed: 17 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06931444.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing